Dynastat - supply shortage
Ongoing
parecoxib
ShortageHuman
Shortage information
There is a shortage of Dynastat in some Members States of the European Union (EU)/European Economic Area (EEA).
Dynastat is a medicine used in adults for the short-term relief of pain after an operation. It is given by injection into a vein or muscle.
For further information on the use of the medicine, please refer to the medicine’s overview page.
The shortage is due to a temporary reduction in the production capacity of Dynastat, following a temporary shutdown of one of the company’s production lines. The manufacturer is currently prioritising supply to markets where shortages are considered critical, with no country in the EU/EEA currently considered critical. Although the affected line has now resumed production, the company will need time to meet the current demand for Dynastat in the EU/EEA.
The shortage is expected to last until May 2025 in the Netherlands and March 2026 in Norway.
The shortage currently affects two EU/EEA countries where the product is marketed: the Netherlands and Norway.
Other EU/EEA countries are at risk of shortage and the above information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and
EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
In addition, the marketing authorisation holder is working to expedite and coordinate the distribution of Dynastat in a way that minimises the impact of shortages and is exploring options to increase its production.
- Before starting treatment, healthcare professionals should ensure that sufficient supplies of Dynastat are available.
- Doctors should consider other medicines for postoperative pain relief if Dynastat is not available in their country, taking into consideration local and national guidance.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- Before starting treatment, your doctor will ensure that sufficient supplies of Dynastat are available.
- If Dynastat is not available in your country, there may be alternative medicines available for the control of pain which your doctor can prescribe.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Key facts
- Medicines affected
- Dynastat
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- parecoxib
- Pharmaceutical forms affected
- Powder and solvent for solution for injection
- Powder for solution for injection
- Strengths affected
- 40 mg
- Availability of alternatives
- Unknown
Key dates
- Expected resolution
- May 2025 in the Netherlands
March 2026 in Norway - First published